<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Germline inherited genes with possible treatment ramifications in metastatic prostate cancer</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Germline inherited genes with possible treatment ramifications in metastatic prostate cancer</h1>
<div class="graphic"><div class="figure"><div class="ttl">Germline inherited genes with possible treatment ramifications in metastatic prostate cancer</div><div class="cntnt"><table cellspacing="0"><colgroup span="7" width="14%"></colgroup> <tbody> <tr> <td class="subtitle1" rowspan="2">Gene</td> <td class="subtitle1" rowspan="2">Association with increased prostate cancer risk</td> <td class="subtitle1" rowspan="2">Association with other cancer risk (eg, breast, ovary, colon, uterus) and management options</td> <td class="subtitle1" rowspan="2">Prevalence of germline mutations in metastatic prostate cancer</td> <td class="subtitle1" rowspan="2">Prevalence of germline mutations in prostate cancer with family history</td> <td class="subtitle1" colspan="2">Treatment implications in metastatic prostate cancer</td> </tr> <tr> <td class="subtitle2">Eligible for DNA-damaging agents: PARP inhibitor, platinum</td> <td class="subtitle2">Eligible for immunotherapy: PD-1 inhibitor</td> </tr> <tr class="centered"> <td><em>ATM</em></td> <td>X</td> <td>X</td> <td>1.6%</td> <td>2.0%</td> <td><strong>X</strong></td> <td> </td> </tr> <tr class="centered"> <td><em>BARD1</em></td> <td> </td> <td> </td> <td> </td> <td> </td> <td><strong>X</strong></td> <td> </td> </tr> <tr class="centered"> <td><em>BRCA1</em></td> <td>X</td> <td>X</td> <td>0.9%</td> <td>0.7%</td> <td><strong>XX</strong></td> <td> </td> </tr> <tr class="centered"> <td><em>BRCA2</em></td> <td>X</td> <td>X</td> <td>5.4%</td> <td>4.7%</td> <td><strong>XX</strong></td> <td> </td> </tr> <tr class="centered"> <td><em>BRIP1</em></td> <td> </td> <td> </td> <td> </td> <td> </td> <td><strong>X</strong></td> <td> </td> </tr> <tr class="centered"> <td><em>CDK12</em></td> <td> </td> <td> </td> <td> </td> <td> </td> <td><strong>X</strong></td> <td> </td> </tr> <tr class="centered"> <td><em>CHEK1</em></td> <td> </td> <td> </td> <td> </td> <td> </td> <td><strong>X</strong></td> <td> </td> </tr> <tr class="centered"> <td><em>CHEK2</em></td> <td>X</td> <td>X</td> <td>1.9%</td> <td>2.9%</td> <td><strong>X</strong></td> <td> </td> </tr> <tr class="centered"> <td><em>FANCL</em></td> <td> </td> <td> </td> <td> </td> <td> </td> <td><strong>X</strong></td> <td> </td> </tr> <tr class="centered"> <td><em>HOXB13</em></td> <td>X</td> <td> </td> <td>Not evaluated</td> <td>1.1%</td> <td> </td> <td> </td> </tr> <tr class="centered"> <td><em>MLH1</em></td> <td>X</td> <td>X</td> <td> </td> <td>0.1%</td> <td> </td> <td><strong>X</strong></td> </tr> <tr class="centered"> <td><em>MSH2</em></td> <td>X</td> <td>X</td> <td>0.1%</td> <td>0.7%</td> <td> </td> <td><strong>X</strong></td> </tr> <tr class="centered"> <td><em>MSH6</em></td> <td>X</td> <td>X</td> <td>0.1%</td> <td>0.5%</td> <td> </td> <td><strong>X</strong></td> </tr> <tr class="centered"> <td><em>NBN</em></td> <td> </td> <td>X</td> <td>0.3%</td> <td>0.3%</td> <td><strong>X</strong></td> <td> </td> </tr> <tr class="centered"> <td><em>PALB2</em></td> <td> </td> <td>X</td> <td>0.4%</td> <td>0.6%</td> <td><strong>X</strong></td> <td> </td> </tr> <tr class="centered"> <td><em>PMS2</em></td> <td>X</td> <td>X</td> <td>0.3%</td> <td>0.5%</td> <td> </td> <td><strong>X</strong></td> </tr> <tr class="centered"> <td><em>RAD51B</em></td> <td> </td> <td> </td> <td> </td> <td> </td> <td><strong>X</strong></td> <td> </td> </tr> <tr class="centered"> <td><em>RAD51C</em></td> <td> </td> <td>X</td> <td>0.1%</td> <td>0.2%</td> <td><strong>X</strong></td> <td> </td> </tr> <tr class="centered"> <td><em>RAD51D</em></td> <td> </td> <td>X</td> <td>0.4%</td> <td>0.2%</td> <td><strong>X</strong></td> <td> </td> </tr> <tr class="centered"> <td><em>RAD54L</em></td> <td> </td> <td> </td> <td> </td> <td> </td> <td><strong>X</strong></td> <td> </td> </tr> </tbody></table></div><div class="graphic_lgnd">In the column entitled Eligible for DNA damaging agents: PARP inhibitor, platinum: <strong>XX</strong> denotes those pathogenic variants that have FDA approval for rucaparib and olaparib; <strong>X</strong> denotes FDA approval for olaparib.</div><div class="graphic_footnotes">PARP: poly-adenosine diphosphate-ribose polymerase; PD-1: programmed cell death 1; <em>ATM</em>: ataxia telangiectasia mutated; <em>BARD1</em>: BRCA1-associated RING domain 1; <em>BRCA</em>: breast cancer susceptibility gene; <em>BRIP</em>: BRCA1-interacting protein c-terminal helicase-1; <em>CDK</em>: cyclin-dependent kinase; <em>CHEK</em>: checkpoint kinase; <em>HOXB13</em>: homeobox B13; <em>MLH1</em>: mutL homolog 1; <em>MSH</em>: mutS homolog; <em>NBN</em>: nibrin; <em>PALB2</em>: partner and localizer of <em>BRCA2</em>; <em>PMS2</em>: postmeiotic segregation increased 2; <em>RAD</em>: recombination protein A; FDA: US Food and Drug Administration.</div><div class="graphic_reference">Adapted with permission of Harborside Press, from Cheng HH, Sokolova AO, Schaeffer EM, et al. Germline and Somatic Mutations in Prostate Cancer for the Clinician. J Natl Compr Canc Netw 2019; 17:515; permission conveyed through Copyright Clearance Center, Inc.</div><div id="graphicVersion">Graphic 126461 Version 5.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
